Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF -0.51%85 3-Year Book Growth Rate is 17.50% as of Jun. 2026, which is 13% above its 10-year median of 15.50. GuruFocus rates CLVLF with a GF Score™ of 85/100 and a GF Value™ of $9.34 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,126 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 83.21% on this metric.
During the past 12 months, Clinuvel Pharmaceuticals's average Book Value per Share Growth Rate was 12.60% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 17.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 22.50% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 30.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Clinuvel Pharmaceuticals was 48.60% per year. The lowest was -31.90% per year. And the median was 15.50% per year.
Clinuvel Pharmaceuticals (OTCPK:CLVLF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Clinuvel Pharmaceuticals 3-Year Book Growth Rate Related Terms
CLVLF vs VRTX, REGN, MRNA: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's 3-Year Book Growth Rate falls into.
Clinuvel Pharmaceuticals 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 17.50% mean?
Clinuvel Pharmaceuticals (CLVLF) has a 3-Year Book Growth Rate of 17.50% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Clinuvel Pharmaceuticals and its competitors. This is 13% above median its historical median of 15.50. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #189 out of 1126 companies in the Biotechnology industry, placing it in the top 16.8%.
Is Clinuvel Pharmaceuticals' 3-Year Book Growth Rate too high?
Clinuvel Pharmaceuticals' current 3-Year Book Growth Rate of 17.50% is 13% above median its 10-year median of 15.50. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #189 out of 1126 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #189 out of 1126 companies for 3-Year Book Growth Rate. This places Clinuvel Pharmaceuticals in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Clinuvel Pharmaceuticals and its competitors. Clinuvel Pharmaceuticals's current 3-Year Book Growth Rate is 17.50%, which is 13% above median its own 10-year median of 15.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.34, compared to a current price of $5.89 — trading 36.9% below its estimated fair value. The current 3-Year Book Growth Rate is 17.50%, which is 13% above median its 10-year median of 15.50. Clinuvel Pharmaceuticals' overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current 3-Year Book Growth Rate is 17.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $5.89 is trading 36.9% below its estimated GF Value™ of $9.34.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
3-Year Book Growth Rate: 17.50% (13% above median its 10-year median of 15.50)
GF Value™: $9.34 vs. price of $5.89 (36.9% below fair value)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
85GF Score
Get the complete analysis for CLVLF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
